Agency selected the MX908 to work closely with local law enforcement to prevent drug smuggling as opioid crisis rages across the country

908 Devices (NASDAQ: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the U.S. Border Patrol selected the MX908^® – a handheld, battery-powered, mass spectrometry device – to standardize its trace drug detection at 20 field locations across the U.S. borders, from North to South and in the Caribbean. The U.S. Border Patrol purchased more than 60 MX908 units, which are designed for rapid analysis of vapor, liquid and solid materials of unknown identity, to prevent drug smuggling and to work with local and state law enforcement in support of its counter drug mission.

The opioid crisis is, unfortunately, worsening. Drug overdose deaths are on the rise, and the CDC estimates that the U.S. suffered an almost 17% increase in drug-related deaths from May 2019 to May 2020, in part, accelerated by the pandemic. This frightening trend further drives the urgency for the point-of-need analysis provided by the MX908.

“We’re proud to support U.S. Border Patrol as they field our MX908 devices across their enterprise to provide their first responders with the ability to better serve and protect our borders and country,” said John Kenneweg, Vice President of Government at 908 Devices. “We’ve seen a rise in the creation and distribution of synthetic opioids in particular because not many technologies can identify drugs at these trace levels. Even as bad actors try to trick the system by slightly tweaking analogs, the MX908 helps U.S. agencies like Border Patrol future proof their mode of drug identification, so that the technology they get trained on today can evolve with them in support of their counter drug mission in the years ahead.”

908 Devices’ MX908 is utilized by a wide spectrum of users for a variety of forensic field applications such as chemical, explosive, priority drug and HazMat operations, detecting materials at the trace level. The agile, multi-purpose device empowers front line workers, military personnel, and public safety officers with real-time intelligence in seconds. Elite responders rely on the company’s handheld devices to combat the opioid crisis, detect counterfeit pharmaceuticals and illicit materials in the air or on surfaces at levels 1,000-times below their lethal dose. The MX908 is the only technology of its kind that can detect more than 2,000 fentanyl analogs, which is critical as fentanyl and its many analogs are largely driving the opioid epidemic.

About 908 Devices

908 Devices is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic separations, software automation, and machine learning. To learn more about 908 Devices, visit: https://908devices.com/.

Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the SEC which are available on the SEC’s website at www.sec.gov. Additional information will be made available in the Company’s annual and quarterly reports and other filings that it makes from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210408005123/en/